Subjective experience, psychopathology, extrapyramidal side effects, quality of life, global functioning and metabolic parameters were assessed at baseline (T0) and 4 months after dose adjustment (T1). A medical doctor, trainee in psychiatry, blind for the intervention, was responsible for all the measurements and was being trained in investigating extra pyramidal side effects and measuring global functioning. Patients receiving depot medication were measured in the same moment in the depot in T0 and T1.